Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Sep 18, 2021 10:03am
225 Views
Post# 33882982

$84B global NASH market by 2029

$84B global NASH market by 2029

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment - Oramed Pharmaceuticals

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment - Oramed Pharmaceuticals

 

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials - Oramed Pharmaceuticals

“The global market for drugs to treat NASH is expected to reach $84 billion by 2029.”

 

This is one way to spread the news.

This company seems to be developing mostly oral drugs for diabetes type 1/2 and patients suffering from both diabetes and NASH. Looking through their PRs there were some mentioning of Covid Vaccin. The company and Premas Biotech created a new company Oravax (preclinical covid so far). In the past 12 months their valuation has appreciated by 670%.

Over 4000 followers on Stocktwits, valuation over $660M, over 800k daily volume.

Point is there are no norms re how to spread  the news. THTX has an open label cancer trial yet they don’t know anything about it’s progress as per the chat with Ed Nash?Their progresses with regulators for NASH seems to be handled by the secret service until now they are trying to bring it back to spot lights! Shares are currently“ridiculously cheap” for a good reason and the reason is…

<< Previous
Bullboard Posts
Next >>